Marvel Biosciences selects Novotech for MB-204 trial

Executive Summary

• Marvel Biosciences Corp. has selected Novotech, an internationally recognized contract research organization (CRO), to manage its upcoming Phase I clinical trial for its lead drug candidate, MB-204.
• The selection of an Australian-based CRO is intended to leverage favorable regulatory environments and significant tax credits (exceeding 40% of costs) to accelerate the Phase I program and maximize capital efficiency.
• MB-204, a patented neuroactive adenosine A2A antagonist, has completed cGMP synthesis and four-week GLP toxicological studies, marking a pivotal transition into human trials for neurodevelopmental disorders.

Key Details

• Partnership: Marvel Biosciences selected Novotech (based in Australia) as the Contract Research Organization (CRO) for the Phase I clinical trial of MB-204.
• CRO Credentials: Novotech was awarded the 2025 Global Biotechnology Contract Research Organization Company of the Year by Frost & Sullivan.
• Drug Candidate (MB-204):
  • Mechanism: Patented neuroactive adenosine A2A antagonist.
  • Development Status: Completed cGMP synthesis and four-week GLP toxicological studies.
  • Indications: Being developed for neurodevelopmental disorders including Rett syndrome, fragile X syndrome, autism spectrum disorder, and depression.
  • Background: MB-204 is a novel fluorinated derivative of istradefylline, an approved Parkinson's drug and the only adenosine A2A receptor blocker currently on the market.
• Strategic Rationale:
  • Australia offers a favorable regulatory environment for first-in-man studies.
  • Tax credits in Australia exceed 40% of the costs incurred, providing significant cost-efficiencies.
  • The partnership aims to accelerate the Phase I program through a streamlined regulatory pathway while maintaining world-class clinical standards.
• Management Commentary: Dr. Mark Williams, Chief Scientific Officer, noted that the company has previously worked with Novotech on multiple clinical programs and is pleased to partner with them again.

Notable Quotes

• "Having previously worked with Novotech on multiple clinical programs, I am pleased to be working with Novotech again," said Dr. Mark Williams, chief scientific officer of Marvel Biosciences. "Australia is an attractive place to conduct first-in-man studies owing to their favourable regulatory environment and tax credits exceeding 40 per cent of the costs incurred there."